128 related articles for article (PubMed ID: 10550551)
1. Clinical effects of monoclonal antibody 17-1A combined with granulocyte/macrophage-colony-stimulating factor and interleukin-2 for treatment of patients with advanced colorectal carcinoma.
Hjelm Skog A; Ragnhammar P; Fagerberg J; Frödin J; Goldinger M; Koldestam H; Liljefors M; Nilsson B; Shetye J; Wersäll P; Mellstedt H
Cancer Immunol Immunother; 1999 Nov; 48(8):463-70. PubMed ID: 10550551
[TBL] [Abstract][Full Text] [Related]
2. Anti-EpCAM monoclonal antibody (MAb17-1A) based treatment combined with alpha-interferon, 5-fluorouracil and granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma.
Liljefors M; Ragnhammar P; Nilsson B; Ullenhag G; Mellstedt H; Frödin JE
Int J Oncol; 2004 Sep; 25(3):703-11. PubMed ID: 15289873
[TBL] [Abstract][Full Text] [Related]
3. Treatment with GM-CSF and IL-2 in patients with metastatic colorectal carcinoma induced high serum levels of neopterin and sIL-2R, an indicator of immune suppression.
Skog AL; Wersäll P; Ragnhammar P; Frödin JE; Mellstedt H
Cancer Immunol Immunother; 2002 Jul; 51(5):255-62. PubMed ID: 12070712
[TBL] [Abstract][Full Text] [Related]
4. MAb17-1A and cytokines for the treatment of patients with colorectal carcinoma.
Frödin JE; Fagerberg J; Hjelm Skog AL; Liljefors M; Ragnhammar P; Mellstedt H
Hybrid Hybridomics; 2002 Apr; 21(2):99-101. PubMed ID: 12031098
[TBL] [Abstract][Full Text] [Related]
5. Granulocyte/macrophage-colony-stimulating factor augments the induction of antibodies, especially anti-idiotypic antibodies, to therapeutic monoclonal antibodies.
Ragnhammar P; Fagerberg J; Frödin JE; Wersäll P; Hansson LO; Mellstedt H
Cancer Immunol Immunother; 1995 Jun; 40(6):367-75. PubMed ID: 7627993
[TBL] [Abstract][Full Text] [Related]
6. Clinical effects of a chimeric anti-EpCAM monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma.
Liljefors M; Nilsson B; Fagerberg J; Ragnhammar P; Mellstedt H; Frödin JE
Int J Oncol; 2005 Jun; 26(6):1581-9. PubMed ID: 15870873
[TBL] [Abstract][Full Text] [Related]
7. Influence of varying doses of granulocyte-macrophage colony-stimulating factor on pharmacokinetics and antibody-dependent cellular cytotoxicity.
Liljefors M; Nilsson B; Mellstedt H; Frödin JE
Cancer Immunol Immunother; 2008 Mar; 57(3):379-88. PubMed ID: 17676322
[TBL] [Abstract][Full Text] [Related]
8. Therapy of colorectal carcinoma with monoclonal antibodies (MAb17-1A) alone and in combination with granulocyte monocyte-colony stimulating factor (GM-CSF).
Mellstedt H; Frödin JE; Ragnhammar P; Masucci G; Ljungberg A; Hjelm AL; Fagerberg J; Lindemalm C; Osterborg A; Wersäll P
Acta Oncol; 1991; 30(8):923-31. PubMed ID: 1777244
[TBL] [Abstract][Full Text] [Related]
9. Effect of monoclonal antibody 17-1A and GM-CSF in patients with advanced colorectal carcinoma--long-lasting, complete remissions can be induced.
Ragnhammar P; Fagerberg J; Frödin JE; Hjelm AL; Lindemalm C; Magnusson I; Masucci G; Mellstedt H
Int J Cancer; 1993 Mar; 53(5):751-8. PubMed ID: 8449598
[TBL] [Abstract][Full Text] [Related]
10. The therapeutic use of the unconjugated monoclonal antibodies (MAb) 17-1A in combination with GM-CSF in the treatment of colorectal carcinoma (CRC).
Ragnhammar P; Magnusson I; Masucci G; Mellstedt H
Med Oncol Tumor Pharmacother; 1993; 10(1-2):61-70. PubMed ID: 8258997
[TBL] [Abstract][Full Text] [Related]
11. Low-dose monoclonal antibody CC49 administered sequentially with granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal cancer.
Rucker R; Bresler HS; Heffelfinger M; Kim JA; Martin EW; Triozzi PL
J Immunother; 1999 Jan; 22(1):80-4. PubMed ID: 9924703
[TBL] [Abstract][Full Text] [Related]
12. Immunopathology of metastases in patients of colorectal carcinoma treated with monoclonal antibody 17-1A and granulocyte macrophage colony-stimulating factor.
Shetye J; Ragnhammar P; Liljefors M; Christensson B; Frödin JE; Biberfeld P; Mellstedt H
Clin Cancer Res; 1998 Aug; 4(8):1921-9. PubMed ID: 9717820
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of immunomodulation with granulocyte-macrophage colony-stimulating factor, interleukin-2, and rituximab following autologous stem cell transplant in patients with relapsed or refractory lymphomas.
Poiré X; Kline J; Grinblatt D; Zimmerman T; Conner K; Muhs C; Gajewski T; Van Besien K; Smith SM
Leuk Lymphoma; 2010 Jul; 51(7):1241-50. PubMed ID: 20496994
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxic functions of blood mononuclear cells in patients with colorectal carcinoma treated with mAb 17-1A and granulocyte/macrophage-colony-stimulating factor.
Ragnhammar P; Masucci G; Frödin JE; Hjelm AL; Mellstedt H
Cancer Immunol Immunother; 1992; 35(3):158-64. PubMed ID: 1638551
[TBL] [Abstract][Full Text] [Related]
15. Granulocyte/macrophage-colony-stimulating-factor plus interleukin-2 plus interferon alpha in the treatment of metastatic renal cell carcinoma: a pilot study.
Westermann J; Reich G; Kopp J; Haus U; Dörken B; Pezzutto A
Cancer Immunol Immunother; 2001 Jan; 49(11):613-20. PubMed ID: 11225992
[TBL] [Abstract][Full Text] [Related]
16. Humoral anti-idiotypic and anti-anti-idiotypic immune response in cancer patients treated with monoclonal antibody 17-1A.
Fagerberg J; Ragnhammar P; Liljefors M; Hjelm AL; Mellstedt H; Frödin JE
Cancer Immunol Immunother; 1996 Feb; 42(2):81-7. PubMed ID: 8620524
[TBL] [Abstract][Full Text] [Related]
17. Phase Ib trial of granulocyte-macrophage colony-stimulating factor combined with murine monoclonal antibody R24 in patients with metastatic melanoma.
Chachoua A; Oratz R; Liebes L; Alter RS; Felice A; Peace D; Vilcek J; Blum RH
J Immunother Emphasis Tumor Immunol; 1994 Aug; 16(2):132-41. PubMed ID: 7804528
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of in vitro and in vivo anti-tumor activity of anti-GD2 monoclonal antibody 220-51 against human neuroblastoma by granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor.
Fukuda M; Horibe K; Furukawa K
Int J Mol Med; 1998 Oct; 2(4):471-5. PubMed ID: 9857237
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity of granulocyte-macrophage colony-stimulating factor (GM-CSF) products in patients undergoing combination therapy with GM-CSF.
Wadhwa M; Skog AL; Bird C; Ragnhammar P; Lilljefors M; Gaines-Das R; Mellstedt H; Thorpe R
Clin Cancer Res; 1999 Jun; 5(6):1353-61. PubMed ID: 10389919
[TBL] [Abstract][Full Text] [Related]
20. Granulocyte-monocyte colony-stimulating-factor augments the interleukin-2-induced cytotoxic activity of human lymphocytes in the absence and presence of mouse or chimeric monoclonal antibodies (mAb 17-1A).
Masucci G; Ragnhammar P; Wersäll P; Mellstedt H
Cancer Immunol Immunother; 1990; 31(4):231-5. PubMed ID: 2199042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]